Evidence map›Paper›PMID 29312797›Full record

ArticleAmerican journal of cancer research2017

Loss of ACVRIB leads to increased squamous cell carcinoma aggressiveness through alterations in cell-cell and cell-matrix adhesion proteins.

Holli A Loomans, Shanna A Arnold, Kate Hebron, Chase J Taylor, Andries Zijlstra, Claudia D Andl

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Holli A LoomansDepartment of Cancer Biology, Vanderbilt UniversityNashville, TN, USA.
Shanna A ArnoldDepartment of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA.
Kate HebronDepartment of Cancer Biology, Vanderbilt UniversityNashville, TN, USA.
Chase J TaylorDepartment of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA.
Andries ZijlstraDepartment of Cancer Biology, Vanderbilt UniversityNashville, TN, USA.
Claudia D AndlDepartment of Cancer Biology, Vanderbilt UniversityNashville, TN, USA.
National Cancer Institute · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
The role of Activin A signaling in esophageal cell invasionR01DK094900 · NIDDK · VANDERBILT UNIVERSITY · PI ANDL, CLAUDIA D · 2012 to 2016
$1.6M
Mechanisms of epithelial-mesenchymal crosstalk during esophageal cell invasionR03DK091491 · NIDDK · VANDERBILT UNIVERSITY · PI ANDL, CLAUDIA D · 2012 to 2013
$153k
Regulation of prostate cancer progression by ALCAM proteolysisF31CA189764 · NCI · VANDERBILT UNIVERSITY · PI HEBRON, KATIE ELIZABETH · 2014 to 2016
$76k
Activin A signaling regulates head and neck squamous cell carcinoma invasion and metastasisF31DE025477 · NIDCR · VANDERBILT UNIVERSITY · PI LOOMANS-KROPP, HOLLI · 2016 to 2017
$35k
ALCAM as a Biomarker of Treatment Response and Progression in Urogenital CancersIK2BX002498 · VA · VETERANS HEALTH ADMINISTRATION · PI ARNOLD, SHANNA ALEXANDRIA · 2015 to 2020
–
BLRD VA IK2 BX002498NCATS NIH HHS UL1 TR000445NCI NIH HHS F31 CA189764NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA068485NIDCR NIH HHS F31 DE025477NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK094900NIDDK NIH HHS R03 DK091491
6 · The paper itself

Abstract

Squamous cell carcinomas of the head and neck (HNSCC) and esophagus (ESCC) pose a global public health issue due to high mortality rates. Unfortunately, little progress has been made in improving patient outcomes. This is partially a result of a lack of understanding the mechanisms that drive SCC progression. Recently, Activin A signaling has been implicated in a number of cancers, yet the role of this pathway in SCC remains poorly understood. We have previously discovered that the Activin A ligand acts as a tumor suppressor when epithelial Activin receptor type IB (ACVRIB) is intact; however, this effect is lost upon ACVRIB downregulation. In the present study, we investigated the function of ACVRIB in the regulation of SCC. Using CRISPR/Cas9-mediated ACVRIB-knockout and knockdown using siRNA, we found an increased capacity to proliferate, migrate, and invade upon ACRIB loss, as ACVRIB-KO cells exhibited an altered cytoskeleton and aberrant expression of E-cadherin and integrins. Based on chemical inhibitor studies, our data suggests that these effects are mediated through ACVRIB-independent signaling via downstream activation of Smad1/5/8 and MEK/ERK. Overall, we present a novel mechanism of SCC progression upon ACVRIB loss by showing that Activin A can transduce a signal in the absence of ACVRIB.

Indexed as

Activin Aadhesioncytoskeleton dynamicssquamous cell carcinomathree-dimensional culture

Identifiers

PMID29312797
PMCPMC5752684
OpenAlexW2981830193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.